HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30
Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...
Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43
BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37
Bicara (BCAX) Q3 2026 Earnings Call Transcript
Bicara Therapeutics Inc. Common Stock Q3 2026 Earnings Call Summary
What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript
Bicara Therapeutics Q3 2026 Earnings Call Transcript
Bicara Therapeutics Q3 EPS $(1.04) Misses $(0.81) Estimate
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.